Role of plasma XXXX as a biomarker in locally advanced @entity0 .

@entity0 @entity1 @entity1096
@entity1096 ( @entity1096 ), a malignancy-associated secreted phosphoprotein, is a prognostic plasma biomarker for survival in metastatic @entity0 @entity1 . We evaluated the role of @entity1096 in @entity0 ( @entity0 ) @entity1 in predicting response to neoadjuvant chemotherapy and association with survival. Fifty-three @entity1 with non-metastatic @entity0 were enrolled in this study and monitored serially for plasma @entity1096 levels by ELISA during neoadjuvant chemotherapy prior to surgery. For fifty @entity1 who had baseline @entity1096 levels available for analysis, the median baseline @entity1096 level was 63.6 ng/ml. Median @entity1 follow up was 45 months and thirteen @entity1 died from metastatic disease. @entity1 with baseline @entity1096 levels >=  63.6 ng/ml were significantly more likely to die of their disease than those with baseline @entity1096 < 63.6 ng/mL (Hazard Ratio = 3.4; 95% confidence interval 1.4-11.3; P = 0.011), and overall, baseline @entity1096 level was significantly associated with survival (P = 0.002). There was little support for value of serial @entity1096 determination in monitoring response to therapy in this @entity1 population. Although the percentage of @entity1 with baseline @entity1096 levels < 63.6 ng/ml was higher in @entity1 with pathological complete response than in those with no response, the difference was not statistically significant (64% and 14%, respectively (P = 0.066)). Thus, baseline plasma @entity1096 level is a prognostic biomarker in this group of @entity0 @entity1 , and could also be helpful in identifying @entity0 @entity1 who will respond to neoadjuvant chemotherapy. Our results call for validation of our findings in large prospective trial data sets.
